March 12, 2026

Prospective Open-Label Safety Study of Edaravone Dexborneol in Filipino Patients With Acute Ischemic Stroke.

Key Result

Edaravone dexborneol exhibited a favorable safety profile in Filipino patients with acute ischemic stroke, with predominantly mild and reversible adverse events.

Key Points

The study aims to evaluate the safety of edaravone dexborneol in Filipino patients experiencing acute ischemic stroke.
Conducted as a prospective open-label study
Focused on Filipino patients diagnosed with acute ischemic stroke
Monitored and documented adverse events during treatment
Edaravone dexborneol showed a favorable safety profile in the population
Adverse events were predominantly mild, transient, and reversible
Findings are consistent with international data, supporting usage in acute stroke management

Structured PICO

Does edaravone dexborneol have a favorable safety profile in Filipino patients with acute ischemic stroke?

Population

Filipino patients with acute ischemic stroke

Intervention

Edaravone dexborneol

Outcome

Safety profile (adverse events)safety

Edaravone dexborneol is safe and well-tolerated in Filipino patients with acute ischemic stroke, supporting its incorporation into local stroke management pathways.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Edaravone dexborneol demonstrated a favorable safety profile in Filipino patients with acute ischemic stroke, with adverse events (AE) predominantly mild, transient, and reversible. These real-world findings align with international data and support their potential incorporation into acute stroke management pathways in the Philippines.

Bookmark